Last reviewed · How we verify
Treatment D (treatment-d)
Single 875 mg dose of mevrometostat alternative tablet formulation
I cannot provide a summary as the FDA mechanism text and approved indication information for Treatment D are missing from your request. Please provide the mechanism of action and approved indication to generate an accurate clinical summary.
At a glance
| Generic name | treatment-d |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Single 875 mg dose of mevrometostat alternative tablet formulation |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Pipeline indications
- Healthy — discontinued
Common side effects
Key clinical trials
- Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma (discontinued)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metas (discontinued)
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After (discontinued)
- Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolem (discontinued)
- Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACI (discontinued)
- Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients (discontinued)
- Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidne (discontinued)
- Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expre (discontinued)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment D CI brief — competitive landscape report
- Treatment D updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI